Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 78 EV-to-EBIT is 18.63 as of Aug. 18, 2026, which is 47% below its 10-year median of 35.44. GuruFocus rates REVXF with a GF Score™ of 78/100 and a GF Value™ of $36.37. The stock has 2 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 51.59% on this metric.
Revenio Group Oyj (OTCPK:REVXF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Revenio Group Oyj's Enterprise Value for the quarter that ended in Mar. 2026 was $645.9 Mil.
Revenio Group Oyj's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revenio Group Oyj EV-to-EBIT Related Terms
Revenio Group Oyj EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Revenio Group Oyj's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's EV-to-EBIT falls into.
Revenio Group Oyj's current Enterprise Value is $460.2 Mil.
Revenio Group Oyj's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revenio Group Oyj (REVXF) has a EV-to-EBIT of 18.63 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Revenio Group Oyj and its competitors. This is 47% below median its historical median of 35.44. Over the past decade, Revenio Group Oyj's EV-to-EBIT has ranged from 14.68 to 95.60. According to the industry distribution chart, Revenio Group Oyj ranks #228 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 48.4%.
Is Revenio Group Oyj's EV-to-EBIT too high?
Revenio Group Oyj's current EV-to-EBIT of 18.63 is 47% below median its 10-year median of 35.44. Over the past 10 years, this metric has ranged from a low of 14.68 to a high of 95.60. The Medical Devices & Instruments industry median EV-to-EBIT is 19.14. Revenio Group Oyj's value of 18.63 is 2.7% below this industry median. Based on the distribution chart, Revenio Group Oyj ranks #228 out of 471 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Revenio Group Oyj has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #228 out of 471 companies for EV-to-EBIT. This puts Revenio Group Oyj in the upper half of its industry. The industry median EV-to-EBIT is 19.14. Revenio Group Oyj's value of 18.63 is 2.7% below this benchmark. Historically, Revenio Group Oyj's own EV-to-EBIT has ranged from 14.68 to 95.60 over the past decade. While the company's 10-year median is 35.44 vs. the industry median of 19.14, Revenio Group Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.14, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current EV-to-EBIT of 18.63 is 2.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current EV-to-EBIT is 18.63, which is 47% below median its own 10-year median of 35.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Revenio Group Oyj (REVXF) has a current EV-to-EBIT of 18.63. The stock's GF Value™ is $36.37, compared to a current price of $16.41 — trading 54.9% below its estimated fair value. The current EV-to-EBIT is 18.63, which is 47% below median its 10-year median of 35.44 and 2.7% below the Medical Devices & Instruments industry median of 19.14. Revenio Group Oyj's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current EV-to-EBIT is 18.63 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 54.9% below its estimated GF Value™ of $36.37.
Key valuation signals for REVXF:
EV-to-EBIT: 18.63 (47% below median its 10-year median of 35.44)
GF Value™: $36.37 vs. price of $16.41 (54.9% below fair value)
Industry Position: 2.7% below the Medical Devices & Instruments median (#228 of 471)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
78GF Score
Get the complete analysis for REVXF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
